ISPOR EU 2019 Winner - Best general poster research presentations
Acute Myeloid Leukaemia (AML) affects all ages with an incidence rate of 5 per 100,000, but is much more frequent in older people. Although AML therapy is one of the most resource-intensive cancer treatments, there are few estimates of the resource use and economic burden.
The objective of this study was to estimate the cost of treatment-resource use and costs associated with sick leave (SL) and early retirement (ER) in patients below the age of 60 years with AML undergoing allogeneic stem cell transplantation (SCT).
A total of 361 patients under 60 years diagnosed with AML undergoing SCT were identified. Patients could undergo SCT at any stage during the disease
(within the 5-year follow up). In the same age group, 319 patients not undergoing SCT were identified. The mean time from diagnosis to SCT was 228 days; the median time to SCT was 154 days.
Among patients diagnosed with AML ≤60 years, healthcare resource utilisation and costs following allogeneic SCT are substantial with an expected 5-year costs per patient estimated at €240,587. Compared to the group of AML patients ≤60 years not undergoing SCT, higher costs in the SCT group are associated with higher survival rates. The highest health care costs were observed within the first year after SCT and were mainly driven by inpatient care, while long term costs were substantially affected by sick leave and early retirement. To our knowledge this is the first report based on real world population data describing long term costs, including societal costs, of SCT in AML.